|
Market Closed -
London S.E.
11:35:15 2026-10-09 EDT
|
5-day change | 1st Jan Change | ||
| 11,998.00 GBX | +0.89% |
|
+1.08% | -12.99% |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 246,254 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -14.44% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 266,300 | 258,629 | 249,992 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -14.42% | -2.88% | -3.34% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 20.6x | 17.6x | 15.7x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.55x | 3.96x | 3.41x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.1x | 1.3x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 3.9x | 3.67x | 3.46x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.22x | 3.86x | 3.52x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.1x | 10.6x | 9.33x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 12.7x | 11.2x | 9.82x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 27.8x | 20x | 17.1x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.6% | 5% | 5.83% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.34 | 3.544 | 3.655 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.1% | 2.23% | 2.3% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.717 | 9.008 | 10.13 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43.3% | 39.3% | 36.1% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,166 | 67,051 | 71,120 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,076 | 24,313 | 26,808 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,037 | 23,157 | 25,468 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 11,897 | 13,838 | 15,530 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 20,045 | 12,375 | 3,738 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 158.77 | 158.77 | 158.77 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.32x | 4.17x | 11.93x | 2.13% | 244B | |
| 33.21x | 12.07x | 24.51x | 0.59% | 1,043B | |
| 28.53x | 6.31x | 18.08x | 2.08% | 618B | |
| 34.51x | 8.02x | 16.59x | 2.55% | 481B | |
| 103.58x | 5.8x | 24.76x | 2.4% | 351B | |
| 19.03x | 4.65x | 11.56x | 2.84% | 338B | |
| 19.78x | 5.2x | 12.8x | 3.06% | 269B | |
| 25.73x | 6.72x | 11.97x | 2.48% | 220B | |
| -44.49x | 6.55x | 25.51x | 2.24% | 182B | |
| 11.12x | 4.07x | 8.49x | 4.56% | 166B | |
| Average | 25.13x | 6.36x | 16.62x | 2.49% | 391.23B | |
| Weighted average by Cap. | 31.02x | 7.60x | 18.50x | 2.04% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
